On April 23, 2026, the Centers for Medicare & Medicaid Services (CMS) and the Food and Drug Administration (FDA) announced a collaboration to expedite reimbursement processes for breakthrough medical devices.
This new pathway is designed specifically for devices that have received breakthrough designation from the FDA, which could significantly improve patient access to innovative treatments.
The initiative reflects ongoing efforts by federal regulators to streamline healthcare services and support advancements in medical technology.